Log in

Relevant bibliographies by topics / Islands of Langerhans – Transplantation / Journal articles

Journal articles on the topic 'Islands of Langerhans – Transplantation'

To see the other types of publications on this topic, follow the link: Islands of Langerhans – Transplantation.

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Islands of Langerhans – Transplantation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sassa, Mariko, Yasuhiro Iwanaga, and Yuichiro Yamada. "3. Transplantation of Island of Langerhans and Regenerative Therapy." Nihon Naika Gakkai Zasshi 98, no. 4 (2009): 817–23. http://dx.doi.org/10.2169/naika.98.817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Voltarelli, Julio C., Carlos E. B. Couri, Maria-Carolina B. Oliveira, Ana-Beatriz P. L. Stracieri, Daniela A. Moraes, Dannielle F. Godoi, Marina A. Coutinho, et al. "Autologous Hematopoietic Stem Cell Transplantation for Type I Diabetes Mellitus." Blood 104, no. 11 (November 16, 2004): 5224. http://dx.doi.org/10.1182/blood.v104.11.5224.5224.

Full text

Abstract:

Abstract Insulin-dependent type I diabetes mellitus (IDDM) is caused by autoimmune destruction of pancreatic β-islet cells mediated by inflammatory T cells. The pathogenic process evolves gradually for several years and becomes symptomatic when most Langerhans islands are destroyed. Antibodies against β-cell antigens (like anti-glutamic acid decarboxylase, GAD) are markers of the autoimmune reaction and levels of proinsulin C-peptide correlate with endogenous insulin secretion. Several immunosuppressive regimens have demonstrated clinical and laboratorial benefit in early onset IDDM, presumably sparing islets reserve, but most responses were transient and long term toxicity limited their continuous use. In view of durable remissions observed in various autoimmune diseases treated with high-dose immunosuppression and autologous hematopoietic stem cell transplantation (AHSCT), we started in December/03 a phase I/II trial of AHSCT in early-onset IDDM. Patients from 12–35 years old with <6 weeks from diagnosis have their peripheral blood stem cells mobilized with 2 g/m2 cyclophosphamide and 10 mcg/kg G-CSF, cryopreserved and reinfused (>2 million/kg) after conditioning with 200 mg/kg cyclophosphamide and 4,5 mg/kg rabbit antithymocyte globulin- ATG (Thymoglobuline, SangStat). End points of the study are insulin needs (U/kg/d), glycosilated hemoglobin levels, anti-GAD titers and C-peptide levels. Four patients have been transplanted and the insulin usage of the first three patients is shown in the Figure. The first patient received high dose of steroids to prevent ATG hypersensitivity and showed increasing needs of insulin after mobilization. The other two patients received minimal (#2) or no (#3) steroid dose during conditioning and showed decreasing needs of insulin after mobilization (Figure). Patient #2 presented bilateral pneumonia while pancytopenic, recovered after treatment with antibiotics and Amphotericin-B but did not require insulin therapy. A fourth patient has just been discharged from the BMT Unit. Immunologic studies in the three patients with longer follow-up showed a progressive shift from Th1 to Th2 cytokine profile after transplantation which could provide a mechanism for the modulation of the autoimmune process by high dose immunosuppression and autologous HSC. In conclusion, the preliminary results are encouraging but must be validated with a larger number of patients (12 planned in this phase) and a longer followup (5 years). Figure Figure

APA, Harvard, Vancouver, ISO, and other styles

3

Kovpak, V. V. "Вплив трансплантації культур клітин на перебіг експериментального цукрового діабету у тварин." Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies 19, no. 78 (April 7, 2017): 41–47. http://dx.doi.org/10.15421/nvlvet7809.

Full text

Abstract:

As we know from the literature data, type 1 diabetes mellitus occurs due to the loss of β-cells of island of Langerhans, manufacturing insulin, by the organism, which causes its deficiency. The treatment of this type of diabetes, even at early stages, lies in the substitution therapy together with a careful control of blood glucose which may last for life. It is for this reason that the cellular technologies as an alternative method of treatment of this pathology are growing more and more relevant.Objective of the study: to study the impact of allogenic transplantation of the cultures of bone marrow, lipid tissue and pancreas cells on the course of experimentally generated diabetes mellitus in animals.Task: 1. To obtain the cultures of bone marrow, lipid tissue and pancreas cells in rats. 2. To compare the impact of allogenic transplantation of the cultures of bone marrow, lipid tissue and pancreas cells in the course of experimentally generated diabetes mellitus in rats. 3. To study the impact of pancreas cells culture on the course of experimental diabetes mellitus in cats.The studies were conducted using clinically healthy animals (30 males of white non-pedigree rats with body weight of 200–250 g, aged 4–5 months; 9 white non-pedigree junior rats aged 12 days; 4 mongrel cats aged 15–17 months) and missed fetuses of cats remained after obstetric aid.Alloxan diabetes was generated by means of single subcutaneous injection of alloxane monohydrate in the dose of 150 mg/kg in the form of 5% solution on citrate buffer (pH 4.5) after preliminary 24-hour absolute diet with free access to water.The cultures of bone marrow and pancreas cells were obtained from the bone marrow of tubular bones and pancreas of puppies aged 12 days correspondingly, lipid tissue – from rats aged 4–5 months. The culture of cats’ pancreas cells was obtained from the pancreas of cat fetuses. Cell culture process was carried out according the standard method in CO2- incubator. Glucose level in blood serum was determined by means of electrochemical analysis.The results of the study. The authors studied the impact of allogenic transplantation cells culture of bone marrow, lipid tissue and pancreas on the course of experimentally generated diabetes mellitus in rats. The study revealed the decrease of glucose level in the blood of the animals under investigation at cell material transplantation. The most efficient culture for experimental diabetes mellitus therapy is the culture of pancreas cells which has become the cause of its further study in cats.During allogenic transplantation cells culture of pancreas in cats the authors observed abrupt decrease of glucose level in the blood of the animals under investigation immediately after cell transplantation with the further approximation to the initial state.The experimental models presented the positive effect of cell culture transplantation providing the grounds for the further implementation of this diabetes mellitus therapy method in the clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

4

Nakagawara, Gizo. "Transplantation of islets of Langerhans." Journal of Hepato-Biliary-Pancreatic Surgery 1, no. 5 (October 1994): 542–45. http://dx.doi.org/10.1007/bf01211917.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Penfornis, Alfred. "Langerhans islet preparation in cell transplantation." Transfusion Science 18, no. 2 (June 1997): 235–41. http://dx.doi.org/10.1016/s0955-3886(97)00016-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Barakat, Hassan, Khaled Al-Roug, Raya Algonaiman, Sami A. Althwab, Hani A. Alfheeaid, Raghad M. Alhomaid, Mona S. Almujaydil, Taqwa Bushnaq, and Tarek A. Ebeid. "Biological Assessment of Stevioside and Sucralose as Sucrose Substitutes for Diabetics on STZ-Induced Diabetes in Rats." Molecules 28, no. 3 (January 17, 2023): 940. http://dx.doi.org/10.3390/molecules28030940.

Full text

Abstract:

Numerous food organizations have identified excessive calorie consumption and accompanying ailments as significant health risks associated with high sugar consumption. Administering stevioside (ST), sucralose (SU), and the two synergically (SU+ST) affected normal rats’ weight gain. In the current study, SU showed the highest undesired effect. Indeed, administering the three treatments to diabetic rats (DR) did not improve the rats’ weight gain. Although, insulin injection synergically with the treatments improved the weight gain, as recorded after three weeks. The best-improving rate was observed in the ST group. After the administration of ST and ST+SU to the DR, the blood glucose level (GL) was positively affected, with SU having no effects on reducing the GL. A considerable reduction in serum insulin (SIL) was noted in the DR+SU group. On the contrary, ST did not negatively affect the SIL, rather an improvement was recorded. In addition, giving SU did not significantly affect the ALT level in the DR or normal rats (NR). A significant improvement in total bilirubin (TBILI) was observed when insulin was injected with ST or SU in DR groups. Further, triglycerides (TG) after administering ST, SU, or ST+SU to NR had no significant difference compared to the control group (NR). Although, the three treatments markedly but not significantly lowered TG in the DR. For total cholesterol (CHO), both DR and NR had no significant effect after the three treatments. No histopathological alterations were recorded in the NR group. Diffuse and severe atrophy of the islands of Langerhans due to depletion of their cells and mild papillary hyperplasia of the pancreatic ducts were represented by a slightly folded ductal basement membrane and newly formed ductules in STZ-DR. Simultaneous atrophy and absence of the cells of islands of Langerhans besides ductal hyperplasia were evident in DR+SU. Hyperplastic ductal epithelium and atrophic Langerhans cells were seen in DR+SU+In. Degeneration and mild atrophy were observed in the islands of Langerhans structures. There was essentially no noticeable change after utilizing ST. A slight shrinkage of the Langerhans’ islets was detected in DR+ST. In DR+ST+In, no histopathological alterations in the islands of Langerhans were recorded. Congestion in the stromal blood vessels associated with degenerative and necrotic changes in the cells of the islands of Langerhans in DR+SU+ST was observed. In NR+SU, congestion of the blood vessels associated with mild atrophy in the islands of Langerhans and dilatation in stromal blood vessels was noticed. In conclusion, ST is safe, and SU should be taken cautiously, such as mixing with ST and/or taken at a very low concentration to avoid its drastic effect on the human body.

APA, Harvard, Vancouver, ISO, and other styles

7

Triponez, F., J. Oberholzer, J. Lou, and P. Morel. "La transplantation d'îlots de Langerhans: quo vadis." Chirurgie 124, no. 1 (February 1999): 5–12. http://dx.doi.org/10.1016/s0001-4001(99)80036-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

PENFORNIS, A. "Langerhans islet preparation in cell transplantation*1." Transfusion Science 18, no. 2 (June 1997): 235–41. http://dx.doi.org/10.1016/s0955-3886(97)90050-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zandi, Parissa, Yves Panis, Dominique Debray, Olivier Bernard, and Didier Houssin. "Pediatric liver transplantation for langerhans' cell histiocytosis." Hepatology 21, no. 1 (January 1995): 129–33. http://dx.doi.org/10.1002/hep.1840210122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

DAVIS, D. J., M. A. MACAULAY, A. S. MACDONALD, and B. L. ESTABROOKS. "ISLETS OF LANGERHANS IN DOG PANCREAS." Transplantation 45, no. 6 (June 1988): 1099–103. http://dx.doi.org/10.1097/00007890-198806000-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Warnock, Garth L., and Jonathan R. T. Lakey. "CRYOPRESERVATION OF HUMAN ISLETS OF LANGERHANS." Transplantation 68, no. 5 (September 1999): 597–98. http://dx.doi.org/10.1097/00007890-199909150-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

QURESHI, F. I., R. HORNIGOLD, J. D. SPENCER, and S. M. HALL. "Langerhans Cells in Dupuytren’s Contracture." Journal of Hand Surgery 26, no. 4 (August 2001): 362–67. http://dx.doi.org/10.1054/jhsb.2000.0518.

Full text

Abstract:

We have examined biopsies of Dupuytren’s contracture palmar fascia, overlying subcutis and skin, and have correlated the distribution of gross macroscopic changes in the hand, mapped pre- and intraoperatively, with light microscopic immunohistochemical findings. We report increased numbers of S100 positive Langerhans cells (an epidermal cell of dendritic lineage) and CD45 positive cells, both in “nodules” and at dermo-epidermal junctions, in the biopsied tissues. This suggests that Langerhans cells migrate from the epidermis into Dupuytren’s contracture tissue, possibly in response to local changes in levels of inflammatory cytokines within the tissue. Our findings, together with other reports of increased numbers of dermal dendrocytes and inflammatory cells in Dupuytren’s contracture tissue, lend circumstantial support to the “extrinsic theory” of the pathogenesis of Dupuytren’s contracture. However, the earliest stages of the disease process have not been defined, and therefore the events which ultimately produce fibrosis in the palmar fascial complex in susceptible individuals could begin in the skin and/or within deeper tissues, especially where there is dysregulation of the immune system.

APA, Harvard, Vancouver, ISO, and other styles

13

Shapiro, A. M. James. "Strategies toward single-donor islets of Langerhans transplantation." Current Opinion in Organ Transplantation 16, no. 6 (December 2011): 627–31. http://dx.doi.org/10.1097/mot.0b013e32834cfb84.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hering, B. J., D. Romann, A. Clarius, M. Brendel, M. Slijepcevic, R. G. Bretzel, and K. Federlin. "Bovine Islets of Langerhans: Potential Source for Transplantation?" Diabetes 38, Supplement_1 (January 1, 1989): 206–8. http://dx.doi.org/10.2337/diab.38.1.s206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Gabbay, E., J. H. Dark, T. Ashcroft, D. Milne, G. J. Gibson, M. Healy, and P. A. Corris. "Recurrence of Langerhans' cell granulomatosis following lung transplantation." Thorax 53, no. 4 (April 1, 1998): 326–27. http://dx.doi.org/10.1136/thx.53.4.326.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

ETIENNE, BÉNÉDICTE, MICHÈLE BERTOCCHI, JEAN-PAUL GAMONDES, FABRICE THÉVENET, CHRISTOPHE BOUDARD, THÉRÈSE WIESENDANGER, ROBERT LOIRE, JEAN BRUNE, and JEAN-FRANÇOIS MORNEX. "Relapsing Pulmonary Langerhans Cell Histiocytosis after Lung Transplantation." American Journal of Respiratory and Critical Care Medicine 157, no. 1 (January 1998): 288–91. http://dx.doi.org/10.1164/ajrccm.157.1.96-12107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Wiedemeier, Stefan, Friederike Ehrhart, Esther Mettler, Gunter Gastrock, Thomas Forst, Matthias M. Weber, Heiko Zimmermann, and Josef Metze. "Encapsulation of Langerhans' islets: Microtechnological developments for transplantation." Engineering in Life Sciences 11, no. 2 (April 2011): 165–73. http://dx.doi.org/10.1002/elsc.201000146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Stoll, Matthias, Mathias Freund, Hansjörg Schmid, Helmut Deicher, Hansjörg Riehm, Hubert Poliwoda, and Hartmut Link. "Allogeneic bone marrow transplantation for Langerhans' cell histiocytosis." Cancer 66, no. 2 (July 15, 1990): 284–88. http://dx.doi.org/10.1002/1097-0142(19900715)66:2<284::aid-cncr2820660215>3.0.co;2-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Tobin, B. W., Rosemary L. Walzem, Steve M. Watkins, S. K. Leeper-Woodford, Cynthia Bruin, and J. R. T. Lakey. "Lipid Metabolism in Human Pancreatic Islets of Langerhans." Transplantation 76, Supplement (August 2003): S65. http://dx.doi.org/10.1097/00007890-200308271-00142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Berney, Thierry, Aileen Caulfield, Jose Oberholzer, Leo Buhler, Christian Toso, and Philippe Morel. "Islet of Langerhans Autotransplantation: Rationale, Results, and New Developments." Graft 4, no. 8 (December 2001): 535–43. http://dx.doi.org/10.1177/152216280100400802.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

MARCHETTI, PIERO, DAVID W. SCHARP, JOYCE LONGWITH, CAROL SWANSON, BARBARA OLACK, ANDRIANI GERASIMIDI-VAZEOU, EDWARD H. FINKE, and PAUL E. LACY. "PREVENTION OF CONTAMINATION OF ISOLATED PORCINE ISLETS OF LANGERHANS." Transplantation 53, no. 6 (June 1992): 1364–65. http://dx.doi.org/10.1097/00007890-199206000-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Diaz-Sarrio, C., N. Salvatella-Danés, M. Castro-Forns, and A. Nadal. "Langerhans cell sarcoma in a patient who underwent transplantation." Journal of the European Academy of Dermatology and Venereology 21, no. 7 (August 2007): 973–76. http://dx.doi.org/10.1111/j.1468-3083.2007.02147.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ichikawa, K., S. Nomura, K. Ishii, M. Okuno, C. Kasai, T. Maekawa, and E. Kadota. "Autologous stem cell transplantation for refractory Langerhans' cell histiocytosis." Bone Marrow Transplantation 40, no. 8 (August 20, 2007): 807–8. http://dx.doi.org/10.1038/sj.bmt.1705822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Gómez-Román, Javier, María Teresa Zarrabeitia, Ana Santurtún, José Antonio Parra, Ainara Azueta Etxebarría, Jose M. Cifrian, and Javier Freire Salinas. "Pulmonary Langerhans cell histiocytosis “de novo” after lung transplantation." Pathology International 67, no. 12 (October 20, 2017): 632–37. http://dx.doi.org/10.1111/pin.12597.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gerő, László. "Őssejtterápia, β-sejt- és Langerhans-sziget-neogenezis: a jövő lehetséges terápiái 1-es típusú diabetesben?" Orvosi Hetilap 157, no. 19 (May 2016): 740–45. http://dx.doi.org/10.1556/650.2016.30440.

Full text

Abstract:

In type 1 diabetic patients perfect normoglycaemia can only be achieved by successful transplantation of the pancreas or Langerhans’ islets. Surgical transplantation of the whole pancreas is an invasive operation exerting great burden on the patients. Transplantation of the islets of Langerhans does not burden the patients but the survival of the islet grafts is limited. Both interventions are hampered by the lack of donor organs. However, much of these difficulties could be overcome by the use of “artificial β-cells” which ought to have an ultrastructure identical with that of natural β-cells and produce and secrete insulin in a glucose dependent manner. At present three such methods are at our disposal: transformation of the ductal cells of the exocrine pancreas into β-cells, development of β-cells from stem-cells, and neogenesis of Langerhans’ islets induced by viral delivery of transcription factors. The author summarises the experience and experimental results obtained with the use of the three methods. Orv. Hetil., 2016, 157(19), 740–745.

APA, Harvard, Vancouver, ISO, and other styles

26

WARNOCK, GARTH L., DEREK W. R. GRAY, PHILIP MCSHANE, MAUREEN PETERS, and PETER J. MORRIS. "SURVIVAL OF CRYOPRESERVED ISOLATED ADULT HUMAN PANCREATIC ISLETS OF LANGERHANS." Transplantation 44, no. 1 (July 1987): 75–82. http://dx.doi.org/10.1097/00007890-198707000-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Meier, Raphael P. H., Ismail Sert, Philippe Morel, Yannick D. Muller, Sophie Borot, Lionel Badet, Christian Toso, Domenico Bosco, and Thierry Berney. "Islet of Langerhans isolation from pediatric and juvenile donor pancreases." Transplant International 27, no. 9 (June 25, 2014): 949–55. http://dx.doi.org/10.1111/tri.12367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Dauriat, Ga??lle, Herv?? Mal, Gabriel Thabut, Jean-Fran??ois Mornex, Michelle Bertocchi, Fran??ois Tronc, Fran??ois Leroy-Ladurie, et al. "Lung Transplantation for Pulmonary Langerhans?? Cell Histiocytosis: A Multicenter Analysis." Transplantation 81, no. 5 (March 2006): 746–50. http://dx.doi.org/10.1097/01.tp.0000200304.64613.af.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Jain, Kanti, Hua Yang, Shirin K. Asina, Suketu G. Patel, Jagdip Desai, Carolyn Diehl, Kurt Stenzel, Barry H. Smith, and Albert L. Rubin. "LONG-TERM PRESERVATION OF ISLETS OF LANGERHANS IN HYDROPHILIC MACROBEADS1." Transplantation 61, no. 4 (February 1996): 532–36. http://dx.doi.org/10.1097/00007890-199602270-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Kader, Nazneen A., Indusarath S., and N. K. Supriya. "Solitary Langerhans cell histiocytosis of liver with sclerosing cholangitis in an adult female." International Journal of Research in Medical Sciences 5, no. 5 (April 26, 2017): 2237. http://dx.doi.org/10.18203/2320-6012.ijrms20171876.

Full text

Abstract:

Liver is affected as a late complication of high risk cases of Langerhans cell histiocytosis. Sclerosing cholangitis is a rare pattern associated with Langerhans cell histiocytosis of liver, which is even rarer in the adult population and has high mortality. The treatment is difficult and may require liver transplantation. We report a unique case of a 40-year-old female who developed sclerosing cholangitis associated with Langerhans cell histiocytosis without any evidence of involvement of other systems. Our patient required only surgery, and had been followed up for two years without recurrence. We could not find any other case of solitary liver involvement of Langerhans cell histiocytosis in literature published so far.

APA, Harvard, Vancouver, ISO, and other styles

31

Buitinga, Mijke, Roman Truckenmüller, Marten A. Engelse, Lorenzo Moroni, Hetty W. M. Ten Hoopen, Clemens A. van Blitterswijk, Eelco JP de Koning, Aart A. van Apeldoorn, and Marcel Karperien. "Microwell Scaffolds for the Extrahepatic Transplantation of Islets of Langerhans." PLoS ONE 8, no. 5 (May 30, 2013): e64772. http://dx.doi.org/10.1371/journal.pone.0064772.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Habib, S. B., J. Congleton, D. Carr, J. Partridge, B. Corrin, D. M. Geddes, N. Banner, M. Yacoub, and M. Burke. "Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation." Thorax 53, no. 4 (April 1, 1998): 323–25. http://dx.doi.org/10.1136/thx.53.4.323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Soler, N., J. A. Barberà, J. Ramirez, M. Batllé, C. Rozman, and R. Rodriguez-Roisin. "Pulmonary Langerhans' cell histiocytosis following autologous haemopoietic progenitor cell transplantation." Respiratory Medicine 92, no. 10 (October 1998): 1253–55. http://dx.doi.org/10.1016/s0954-6111(98)90430-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kirkorian, Y., M. Collin, M. Leboeuf, M. Bogunovic, B. Wood, R. C. Hackman, B. Storer, R. Storb, M. Merad, and M. Mielcarek. "Langerhans Cell Chimerism After Myeloablative Versus Nonmyeloablative Hematopoietic Cell Transplantation." Biology of Blood and Marrow Transplantation 15, no. 2 (February 2009): 8. http://dx.doi.org/10.1016/j.bbmt.2008.12.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Braier, Jorge, Mirta Ciocca, Antonio Latella, Maria G. de Davila, Marina Drajer, and Oscar Imventarza. "Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis." Medical and Pediatric Oncology 38, no. 3 (February 5, 2002): 178–82. http://dx.doi.org/10.1002/mpo.1306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Thomson, P. C., A. H. M. Taylor, S. T. W. Morris, D. Kipgen, and R. A. Mactier. "AA amyloidosis in a patient with Langerhans cell histiocytosis." Clinical Kidney Journal 4, no. 2 (February 1, 2011): 104–6. http://dx.doi.org/10.1093/ndtplus/sfq201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kopska, T., V. Fürstova, and J. Kovar. "Modified Method for Isolation of Langerhans Islets From Mice." Transplantation Proceedings 40, no. 10 (December 2008): 3611–14. http://dx.doi.org/10.1016/j.transproceed.2008.04.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Akkari, V., J. Donadieu, C. Piguet, P. Bordigoni, G. Michel, S. Blanche, J. L. Casanova, et al. "Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group." Bone Marrow Transplantation 31, no. 12 (June 2003): 1097–103. http://dx.doi.org/10.1038/sj.bmt.1704065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "SUCCESSFUL ORTHOTOPIC LIVER TRANSPLANTATION IN A CHILD WITH LANGERHANS CELL HISTIOCYTOSIS." Transplantation 51, no. 1 (January 1991): 278–80. http://dx.doi.org/10.1097/00007890-199101000-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Meier, Raphael P. H., Jeremy Meyer, Yannick D. Muller, Gregory L. Szot, Benoît Bédat, Axel Andres, Nathalie Massé, et al. "Pancreas collagen digestion during islet of Langerhans isolation—a prospective study." Transplant International 33, no. 11 (September 28, 2020): 1516–28. http://dx.doi.org/10.1111/tri.13725.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bennet, W., C.-G. Groth, B. Sundberg, Z. Song, R. Larsson, B. Nilsson, and O. Korsgren. "Rapid Destruction of Porcine Islets of Langerhans by Fresh Human Blood." Transplantation 65, Supplement (May 1998): 199. http://dx.doi.org/10.1097/00007890-199805131-00482.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Shyr, Y.-M. "GENERATION OF FUNCTIONAL NEOISLETS OF LANGERHANS FROM SURGICAL RESECTED PANCREATIC TISSUE." Transplantation 86, Supplement (July 2008): 564. http://dx.doi.org/10.1097/01.tp.0000331039.38944.de.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "RESPONSE TO ARGININE STIMULATION TEST PREDICTS ISLET OF LANGERHANS GRAFT OUTCOME." Transplantation 82, Suppl 2 (July 2006): 579. http://dx.doi.org/10.1097/00007890-200607152-01529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bennet, W., C. G. Groth, B. Sundberg, Z. Song, R. Larsson, B. Nilsson, and O. Korsgren. "Rapid Destruction of Porcine Islets of Langerhans by Fresh Human Blood." Transplantation 65, no. 12 (June 1998): S123. http://dx.doi.org/10.1097/00007890-199806270-00503.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Da Silva Xavier, Gabriela. "The Cells of the Islets of Langerhans." Journal of Clinical Medicine 7, no. 3 (March 12, 2018): 54. http://dx.doi.org/10.3390/jcm7030054.

Full text

Abstract:

Islets of Langerhans are islands of endocrine cells scattered throughout the pancreas. A number of new studies have pointed to the potential for conversion of non-β islet cells in to insulin-producing β-cells to replenish β-cell mass as a means to treat diabetes. Understanding normal islet cell mass and function is important to help advance such treatment modalities: what should be the target islet/β-cell mass, does islet architecture matter to energy homeostasis, and what may happen if we lose a particular population of islet cells in favour of β-cells? These are all questions to which we will need answers for islet replacement therapy by transdifferentiation of non-β islet cells to be a reality in humans. We know a fair amount about the biology of β-cells but not quite as much about the other islet cell types. Until recently, we have not had a good grasp of islet mass and distribution in the human pancreas. In this review, we will look at current data on islet cells, focussing more on non-β cells, and on human pancreatic islet mass and distribution.

APA, Harvard, Vancouver, ISO, and other styles

46

ZEKORN, TOBIAS, ULRIKE SIEBERS, REINHARD G. BRETZEL, MONIKA RENARDY, HEINRICH PLANCK, PETER ZSCHOCKE, and KONRAD FEDERLIN. "PROTECTION OF ISLETS OF LANGERHANS FROM INTERLEUKIN-1 TOXICITY BY ARTIFICIAL MEMBRANES." Transplantation 50, no. 3 (September 1990): 391–93. http://dx.doi.org/10.1097/00007890-199009000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Jontell, Mats, Håkan Gäbel, Sven-Christer Öhman, and Hans Brynger. "Class II antigen expression of epidermal Langerhans cells in renal allograft recipients." Transplant International 1, no. 1 (January 1988): 186–89. http://dx.doi.org/10.1111/j.1432-2277.1988.tb01813.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Hadzic, Nedim, Jon Pritchard, David Webb, Bernard Portmann, Nigel D. Heaton, Mohamed Rela, Anil Dhawan, Alastair J. Baker, and Giorgina Mieli-Vergani. "RECURRENCE OF LANGERHANS CELL HISTIOCYTOSIS IN THE GRAFT AFTER PEDIATRIC LIVER TRANSPLANTATION." Transplantation 70, no. 5 (September 2000): 815–19. http://dx.doi.org/10.1097/00007890-200009150-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Melendez, Hector Vilca, Anil Dhawan, Giorgina Mieli-Vergani, Mohamed Rela, Nigel D. Heaton, Jon Pritchard, and Alex Mowat. "LIVER TRANSPLANTATION FOR LANGERHANS' CELL HISTIOCYTOSIS-A CASE REPORT AND LITERATURE REVIEW." Transplantation 62, no. 8 (October 1996): 1167–71. http://dx.doi.org/10.1097/00007890-199610270-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

JIAO, LONG, DEREK W. R. GRAY, WOLFGANG GOHDE, GREG J. FLYNN, and PETER J. MORRIS. "IN VITRO STAINING OF ISLETS OF LANGERHANS FOR FLUORESCENCE-ACTIVATED CELL SORTING." Transplantation 52, no. 3 (September 1991): 450–52. http://dx.doi.org/10.1097/00007890-199109000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!